{"abstracts-retrieval-response": {"item": {"ait:process-info": {"ait:status": {"@state": "update", "@type": "core", "@stage": "S300"}, "ait:date-delivered": {"@day": "21", "@timestamp": "2022-03-21T13:12:23.000023-04:00", "@year": "2022", "@month": "03"}, "ait:date-sort": {"@day": "03", "@year": "2017", "@month": "01"}}, "bibrecord": {"head": {"author-group": [{"affiliation": {"country": "United States", "address-part": "1600 Divisadero St", "postal-code": "94127", "@afid": "60029881", "@country": "usa", "city": "San Francisco", "organization": [{"$": "University of California"}, {"$": "San Francisco Helen Diller Family Comprehensive Cancer Center"}], "affiliation-id": {"@afid": "60029881"}, "state": "CA"}, "author": [{"ce:given-name": "Hope S.", "preferred-name": {"ce:given-name": "Hope S.", "ce:initials": "H.S.", "ce:surname": "Rugo", "ce:indexed-name": "Rugo H.S."}, "@seq": "1", "ce:initials": "H.S.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD", "ce:surname": "Rugo", "@auid": "57200920500", "ce:indexed-name": "Rugo H.S."}]}, {"affiliation": {"country": "India", "@afid": "121837736", "@country": "ind", "city": "Bangalore", "organization": {"$": "Biocon Research Limited"}, "affiliation-id": {"@afid": "121837736"}}, "author": [{"ce:given-name": "Abhijit", "preferred-name": {"ce:given-name": "Abhijit", "ce:initials": "A.", "ce:surname": "Barve", "ce:indexed-name": "Barve A."}, "@seq": "2", "ce:initials": "A.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD, PhD, MBA", "ce:surname": "Barve", "@auid": "56670991200", "ce:indexed-name": "Barve A."}, {"ce:given-name": "Mudgal", "preferred-name": {"ce:given-name": "Mudgal", "ce:initials": "M.", "ce:surname": "Kothekar", "ce:indexed-name": "Kothekar M."}, "@seq": "9", "ce:initials": "M.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD", "ce:surname": "Kothekar", "@auid": "57192835755", "ce:indexed-name": "Kothekar M."}, {"ce:given-name": "Subramanian", "preferred-name": {"ce:given-name": "Subramanian", "ce:initials": "S.", "ce:surname": "Loganathan", "ce:indexed-name": "Loganathan S."}, "@seq": "10", "ce:initials": "S.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD", "ce:surname": "Loganathan", "@auid": "57218253315", "ce:indexed-name": "Loganathan S."}]}, {"affiliation": {"country": "United States", "@afid": "60086729", "@country": "usa", "city": "Canonsburg", "organization": {"$": "Now with Mylan Inc"}, "affiliation-id": {"@afid": "60086729"}, "state": "PA"}, "author": [{"ce:given-name": "Abhijit", "preferred-name": {"ce:given-name": "Abhijit", "ce:initials": "A.", "ce:surname": "Barve", "ce:indexed-name": "Barve A."}, "@seq": "2", "ce:initials": "A.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD, PhD, MBA", "ce:surname": "Barve", "@auid": "56670991200", "ce:indexed-name": "Barve A."}]}, {"affiliation": {"country": "Germany", "@afid": "60024805", "@country": "deu", "city": "Freiburg", "organization": [{"$": "Department of Haematology"}, {"$": "Oncology"}, {"$": "and Stem Cell Transplantation"}, {"$": "University Medical Centre Freiburg"}, {"$": "Faculty of Medicine"}, {"$": "University of Freiburg"}], "affiliation-id": [{"@afid": "60024805", "@dptid": "113874999"}, {"@afid": "60101437"}, {"@afid": "60025641"}], "@dptid": "113874999"}, "author": [{"ce:given-name": "Cornelius F.", "preferred-name": {"ce:given-name": "Cornelius F.", "ce:initials": "C.F.", "ce:surname": "Waller", "ce:indexed-name": "Waller C.F."}, "@seq": "3", "ce:initials": "C.F.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD", "ce:surname": "Waller", "@auid": "7006001726", "ce:indexed-name": "Waller C.F."}]}, {"affiliation": {"country": "Spain", "@afid": "113802190", "@country": "esp", "city": "Barcelona", "organization": {"$": "Quiron-Dexeus"}, "affiliation-id": {"@afid": "113802190"}}, "author": [{"ce:given-name": "Miguel", "preferred-name": {"ce:given-name": "Miguel", "ce:initials": "M.", "ce:surname": "Hernandez-Bronchud", "ce:indexed-name": "Hernandez-Bronchud M."}, "@seq": "4", "ce:initials": "M.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD, PhD", "ce:surname": "Hernandez-Bronchud", "@auid": "6602840533", "ce:indexed-name": "Hernandez-Bronchud M."}]}, {"affiliation": {"country": "United States", "@afid": "60006183", "@country": "usa", "city": "Baltimore", "organization": [{"$": "Bloomberg School of Public Health"}, {"$": "Johns Hopkins University"}], "affiliation-id": [{"@afid": "60006183"}, {"@afid": "60005248"}], "state": "MD"}, "author": [{"ce:given-name": "Jay", "preferred-name": {"ce:given-name": "Jay", "ce:initials": "J.", "ce:surname": "Herson", "ce:indexed-name": "Herson J."}, "@seq": "5", "ce:initials": "J.", "@date-locked": "2018-02-05T16:13:54.433", "@_fa": "true", "@type": "auth", "ce:degrees": "PhD", "ce:surname": "Herson", "@auid": "7004312660", "ce:indexed-name": "Herson J."}]}, {"affiliation": {"country": "United States", "@afid": "60086729", "@country": "usa", "city": "Canonsburg", "organization": {"$": "Mylan Inc"}, "affiliation-id": {"@afid": "60086729"}, "state": "PA"}, "author": [{"ce:given-name": "Jinyu", "preferred-name": {"ce:given-name": "Jinyu", "ce:initials": "J.", "ce:surname": "Yuan", "ce:indexed-name": "Yuan J."}, "@seq": "6", "ce:initials": "J.", "@_fa": "true", "@type": "auth", "ce:degrees": "PhD", "ce:surname": "Yuan", "@auid": "57192835540", "ce:indexed-name": "Yuan J."}, {"ce:given-name": "Rajiv", "preferred-name": {"ce:given-name": "Rajiv", "ce:initials": "R.", "ce:surname": "Sharma", "ce:indexed-name": "Sharma R."}, "@seq": "7", "ce:initials": "R.", "@_fa": "true", "@type": "auth", "ce:degrees": "MBBS, MS", "ce:surname": "Sharma", "@auid": "57192835055", "ce:indexed-name": "Sharma R."}, {"ce:given-name": "Mark", "preferred-name": {"ce:given-name": "Mark", "ce:initials": "M.", "ce:surname": "Baczkowski", "ce:indexed-name": "Baczkowski M."}, "@seq": "8", "ce:initials": "M.", "@_fa": "true", "@type": "auth", "ce:degrees": "MS, RPh", "ce:surname": "Baczkowski", "@auid": "57192833633", "ce:indexed-name": "Baczkowski M."}, {"ce:given-name": "Eduardo", "preferred-name": {"ce:given-name": "Eduardo", "ce:initials": "E.", "ce:surname": "Pennella", "ce:indexed-name": "Pennella E."}, "@seq": "24", "ce:initials": "E.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD, MBA", "ce:surname": "Pennella", "@auid": "57217897584", "ce:indexed-name": "Pennella E."}]}, {"affiliation": {"country": "Russian Federation", "@afid": "112632857", "@country": "rus", "city": "Saint-Petersburg", "organization": {"$": "City Clinical Oncology Dispensary"}, "affiliation-id": {"@afid": "112632857"}}, "author": [{"ce:given-name": "Alexey", "preferred-name": {"ce:given-name": "Alexey", "ce:initials": "A.", "ce:surname": "Manikhas", "ce:indexed-name": "Manikhas A."}, "@seq": "11", "ce:initials": "A.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD", "ce:surname": "Manikhas", "@auid": "6507130338", "ce:indexed-name": "Manikhas A."}]}, {"affiliation": {"country": "Ukraine", "@afid": "60070090", "@country": "ukr", "city": "Dnipropetrovsk", "organization": {"$": "Dnipropetrovsk State Medical Academy"}, "affiliation-id": {"@afid": "60070090"}}, "author": [{"ce:given-name": "Igor", "preferred-name": {"ce:given-name": "Igor", "ce:initials": "I.", "ce:surname": "Bondarenko", "ce:indexed-name": "Bondarenko I."}, "@seq": "12", "ce:initials": "I.", "@date-locked": "2019-08-26T12:06:50.931", "@_fa": "true", "@type": "auth", "ce:degrees": "MD", "ce:surname": "Bondarenko", "@auid": "24729417400", "ce:indexed-name": "Bondarenko I."}]}, {"affiliation": {"country": "Russian Federation", "@afid": "112755585", "@country": "rus", "city": "Kazan", "organization": {"$": "Regional Clinical Oncological Center"}, "affiliation-id": {"@afid": "112755585"}}, "author": [{"ce:given-name": "Guzel", "preferred-name": {"ce:given-name": "Guzel", "ce:initials": "G.", "ce:surname": "Mukhametshina", "ce:indexed-name": "Mukhametshina G."}, "@seq": "13", "ce:initials": "G.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD", "ce:surname": "Mukhametshina", "@auid": "57215937870", "ce:indexed-name": "Mukhametshina G."}]}, {"affiliation": {"country": "Georgia", "@afid": "101407268", "@country": "geo", "city": "Tbilisi", "organization": {"$": "Institute of Clinical Oncology"}, "affiliation-id": {"@afid": "101407268"}}, "author": [{"ce:given-name": "Gia", "preferred-name": {"ce:given-name": "Gia", "ce:initials": "G.", "ce:surname": "Nemsadze", "ce:indexed-name": "Nemsadze G."}, "@seq": "14", "ce:initials": "G.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD, PhD", "ce:surname": "Nemsadze", "@auid": "57188567636", "ce:indexed-name": "Nemsadze G."}]}, {"affiliation": {"country": "Philippines", "@afid": "112662036", "@country": "phl", "city": "Taguig City", "organization": {"$": "St Luke's Medical Center Global City"}, "affiliation-id": {"@afid": "112662036"}}, "author": [{"ce:given-name": "Joseph D.", "preferred-name": {"ce:given-name": "Joseph D.", "ce:initials": "J.D.", "ce:surname": "Parra", "ce:indexed-name": "Parra J.D."}, "@seq": "15", "ce:initials": "J.D.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD", "ce:surname": "Parra", "@auid": "57192829649", "ce:indexed-name": "Parra J.D."}]}, {"affiliation": {"country": "Philippines", "@afid": "127843511", "@country": "phl", "city": "Manila", "organization": {"$": "Cardinal Santos Medical Center"}, "affiliation-id": {"@afid": "127843511"}}, "author": [{"ce:given-name": "Maria Luisa T.", "preferred-name": {"ce:given-name": "Maria Luisa T.", "ce:initials": "M.L.T.", "ce:surname": "Abesamis-Tiambeng", "ce:indexed-name": "Abesamis-Tiambeng M.L.T."}, "@seq": "16", "ce:initials": "M.L.T.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD", "ce:surname": "Abesamis-Tiambeng", "@auid": "57192835193", "ce:indexed-name": "Abesamis-Tiambeng M.L.T."}]}, {"affiliation": {"country": "Georgia", "@afid": "117925630", "@country": "geo", "city": "Tbilisi", "organization": {"$": "Golden Fleece 21 Century Health House Ltd"}, "affiliation-id": {"@afid": "117925630"}}, "author": [{"ce:given-name": "Kakhaber", "preferred-name": {"ce:given-name": "Kakhaber", "ce:initials": "K.", "ce:surname": "Baramidze", "ce:indexed-name": "Baramidze K."}, "@seq": "17", "ce:initials": "K.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD, PhD", "ce:surname": "Baramidze", "@auid": "57192832810", "ce:indexed-name": "Baramidze K."}]}, {"affiliation": {"country": "Thailand", "@afid": "60199575", "@country": "tha", "city": "Bangkok", "organization": {"$": "Siriraj Hospital"}, "affiliation-id": {"@afid": "60199575"}}, "author": [{"ce:given-name": "Charuwan", "preferred-name": {"ce:given-name": "Charuwan", "ce:initials": "C.", "ce:surname": "Akewanlop", "ce:indexed-name": "Akewanlop C."}, "@seq": "18", "ce:initials": "C.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD", "ce:surname": "Akewanlop", "@auid": "6507727204", "ce:indexed-name": "Akewanlop C."}]}, {"affiliation": {"country": "Ukraine", "@afid": "60016511", "@country": "ukr", "city": "Sumy", "organization": {"$": "Sumy State University"}, "affiliation-id": {"@afid": "60016511"}}, "author": [{"ce:given-name": "Ihor", "preferred-name": {"ce:given-name": "Ihor", "ce:initials": "I.", "ce:surname": "Vynnychenko", "ce:indexed-name": "Vynnychenko I."}, "@seq": "19", "ce:initials": "I.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD", "ce:surname": "Vynnychenko", "@auid": "24781268000", "ce:indexed-name": "Vynnychenko I."}]}, {"affiliation": {"country": "Thailand", "@afid": "60028190", "@country": "tha", "city": "Bangkok", "organization": [{"$": "King Chulalongkorn Memorial Hospital"}, {"$": "Chulalongkorn University"}], "affiliation-id": [{"@afid": "60028190"}, {"@afid": "60022183"}]}, "author": [{"ce:given-name": "Virote", "preferred-name": {"ce:given-name": "Virote", "ce:initials": "V.", "ce:surname": "Sriuranpong", "ce:indexed-name": "Sriuranpong V."}, "@seq": "20", "ce:initials": "V.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD", "ce:surname": "Sriuranpong", "@auid": "6603599644", "ce:indexed-name": "Sriuranpong V."}]}, {"affiliation": {"country": "India", "@afid": "114003460", "@country": "ind", "city": "Vijayawada", "organization": {"$": "City Cancer Center"}, "affiliation-id": {"@afid": "114003460"}}, "author": [{"ce:given-name": "Gopichand", "preferred-name": {"ce:given-name": "Gopichand", "ce:initials": "G.", "ce:surname": "Mamillapalli", "ce:indexed-name": "Mamillapalli G."}, "@seq": "21", "ce:initials": "G.", "@_fa": "true", "@type": "auth", "ce:degrees": "MS, MCh", "ce:surname": "Mamillapalli", "@auid": "57192832827", "ce:indexed-name": "Mamillapalli G."}]}, {"affiliation": {"country": "India", "@afid": "112923297", "@country": "ind", "city": "Nasik", "organization": {"$": "Curie Manavata Cancer Centre"}, "affiliation-id": {"@afid": "112923297"}}, "author": [{"ce:given-name": "Sirshendu", "preferred-name": {"ce:given-name": "Sirshendu", "ce:initials": "S.", "ce:surname": "Ray", "ce:indexed-name": "Ray S."}, "@seq": "22", "ce:initials": "S.", "@_fa": "true", "@type": "auth", "ce:degrees": "MS", "ce:surname": "Ray", "@auid": "57214048627", "ce:indexed-name": "Ray S."}]}, {"affiliation": {"country": "Chile", "@afid": "110207140", "@country": "chl", "city": "Temuco", "organization": {"$": "Instituto Clinico Oncologico Del sur"}, "affiliation-id": {"@afid": "110207140"}}, "author": [{"ce:given-name": "Eduardo P.", "preferred-name": {"ce:given-name": "Eduardo P.", "ce:initials": "E.P.", "ce:surname": "Yanez Ruiz", "ce:indexed-name": "Yanez Ruiz E.P."}, "@seq": "23", "ce:initials": "E.P.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD", "ce:surname": "Yanez Ruiz", "@auid": "57192839215", "ce:indexed-name": "Yanez Ruiz E.P."}]}], "citation-title": "Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: A randomized clinical trial", "abstracts": "IMPORTANCE Treatment with the anti-ERBB2 humanized monoclonal antibody trastuzumab and chemotherapy significantly improves outcome in patients with ERBB2 (HER2)-positive metastatic breast cancer; a clinically effective biosimilar may help increase access to this therapy. OBJECTIVE To compare the overall response rate and assess the safety of a proposed trastuzumab biosimilar plus a taxane or trastuzumab plus a taxane in patients without prior treatment for ERBB2-positivemetastatic breast cancer. DESIGN, SETTING, AND PARTICIPANTS Multicenter, double-blind, randomized, parallel-group, phase 3 equivalence study in patients with metastatic breast cancer. From December 2012 to August 2015, 500 patients were randomized 1:1 to receive a proposed biosimilar or trastuzumab plus a taxane. Chemotherapy was administered for at least 24 weeks followed by antibody alone until unacceptable toxic effects or disease progression occurred. INTERVENTIONS Proposed biosimilar (n = 230) or trastuzumab (n = 228) with a taxane. MAIN OUTCOMES AND MEASURES The primary outcomewasweek 24 overall response rate (ORR) defined as complete or partial response. Equivalence boundaries were 0.81 to 1.24 with a 90% CI for ORR ratio (proposed biosimilar/trastuzumab) and -15%to 15%with a 95% CI for ORR difference. Secondary outcome measures included time to tumor progression, progression-free and overall survival at week 48, and adverse events. RESULTS Among500women randomized, the intention-to-treat population included 458 women (mean [SD] age, 53.6 [11.11] years) and the safety population included 493women. TheORRwas 69.6%(95%CI, 63.62%-75.51%) for the proposed biosimilar vs 64.0%(95%CI, 57.81%-70.26%) for trastuzumab. TheORRratio (1.09;90%CI,0.974-1.211) andORRdifference (5.53; 95%CI, -3.08 to 14.04)were within the equivalence boundaries.Atweek 48, therewas no statistically significant difference with the proposed biosimilar vs trastuzumab for time to tumor progression (41.3%vs 43.0%; -1.7%; 95%CI, -11.1%to 6.9%), progression-free survival (44.3% vs 44.7%; -0.4%; 95%CI, -9.4%to 8.7%), or overall survival (89.1%vs 85.1%; 4.0%; 95%CI, -2.1%to 10.3%). In the proposed biosimilar and trastuzumab groups, 239 (98.6%) and 233 (94.7%) had at least 1 adverse event, the mostcommonincluding neutropenia (57.5%vs 53.3%), peripheral neuropathy (23.1%vs 24.8%), and diarrhea (20.6%vs 20.7%). CONCLUSIONS AND RELEVANCE Amongwomen with ERBB2-positivemetastatic breast cancer receiving taxanes, the use of a proposed trastuzumab biosimilar compared with trastuzumab resulted in an equivalent overall response rate at 24 weeks. Further study is needed to assess safety and long-term clinical outcome.", "correspondence": {"affiliation": {"country": "United States", "address-part": "1600 Divisadero St", "postal-code": "94127", "@country": "usa", "city": "San Francisco", "organization": [{"$": "University of California"}, {"$": "San Francisco Helen Diller Family Comprehensive Cancer Center"}], "state": "CA"}, "person": {"ce:given-name": "Hope S.", "ce:initials": "H.S.", "ce:degrees": "MD", "ce:surname": "Rugo", "ce:indexed-name": "Rugo H.S."}}, "citation-info": {"citation-type": {"@code": "ar"}, "citation-language": {"@language": "English", "@xml:lang": "eng"}, "abstract-language": {"@language": "English", "@xml:lang": "eng"}}, "source": {"website": {"ce:e-address": {"$": "http://jama.jamanetwork.com/journal.aspx", "@type": "email"}}, "translated-sourcetitle": {"$": "JAMA - Journal of the American Medical Association", "@xml:lang": "eng"}, "volisspag": {"voliss": {"@volume": "317", "@issue": "1"}, "pagerange": {"@first": "37", "@last": "47"}}, "@type": "j", "sourcetitle": "JAMA - Journal of the American Medical Association", "publicationdate": {"month": "01", "year": "2017", "date-text": {"@xfab-added": "true", "$": "3 January 2017"}, "day": "03"}, "codencode": "JAMAA", "sourcetitle-abbrev": "JAMA", "@country": "usa", "issn": [{"$": "15383598", "@type": "electronic"}, {"$": "00987484", "@type": "print"}], "publicationyear": {"@first": "2017"}, "publisher": {"publishername": "American Medical Association"}, "@srcid": "85291"}, "enhancement": {"classificationgroup": {"classifications": [{"@type": "CABSCLASS", "classification": [{"classification-code": "86.9.3.8", "classification-description": "IMMUNOLOGY AND INFECTIOUS DISEASES; TUMOUR IMMUNOLOGY; Tumour Immunotherapy; Monoclonal antibodies - therapeutic applications"}, {"classification-code": "87.4.3.8", "classification-description": "CANCER RESEARCH; TREATMENT; Immunotherapy; Monoclonal antibodies - therapeutic applications"}, {"classification-code": "87.5.11", "classification-description": "CANCER RESEARCH; CLINICAL INVESTIGATIONS BY ORGAN SITE; Breast"}]}, {"@type": "EMCLASS", "classification": [{"classification-code": "16", "classification-description": "Cancer"}, {"classification-code": "30", "classification-description": "Clinical and Experimental Pharmacology"}, {"classification-code": "37", "classification-description": "Drug Literature Index"}, {"classification-code": "38", "classification-description": "Adverse Reactions Titles"}]}, {"@type": "ASJC", "classification": "2700"}, {"@type": "SUBJABBR", "classification": "MEDI"}]}, "tradenamegroup": {"tradenames": {"trademanuitem": {"tradename": "herceptin", "manufacturer": "Hoffmann La Roche"}, "@type": "TNM"}}, "chemicalgroup": {"chemicals": [{"@source": "esbd", "chemical": [{"cas-registry-number": [{"$": "9000-86-6"}, {"$": "9014-30-6"}], "enzyme-commission-number": "EC 2.6.1.2", "chemical-name": "alanine aminotransferase"}, {"cas-registry-number": "9000-97-9", "enzyme-commission-number": "EC 2.6.1.1", "chemical-name": "aspartate aminotransferase"}, {"cas-registry-number": "114977-28-5", "chemical-name": "docetaxel"}, {"cas-registry-number": "137632-09-8", "chemical-name": "epidermal growth factor receptor 2"}, {"cas-registry-number": "33069-62-4", "chemical-name": "paclitaxel"}, {"cas-registry-number": [{"$": "180288-69-1"}, {"$": "1446410-98-5"}], "chemical-name": "trastuzumab"}, {"cas-registry-number": "180288-69-1", "chemical-name": "trastuzumab"}]}, {"@source": "nlm", "chemical": [{"chemical-name": "Antineoplastic Agents"}, {"chemical-name": "Antineoplastic Agents, Phytogenic"}, {"chemical-name": "Biosimilar Pharmaceuticals"}, {"chemical-name": "docetaxel"}, {"chemical-name": "ERBB2 protein, human"}, {"chemical-name": "Paclitaxel"}, {"chemical-name": "Receptor, ErbB-2"}, {"chemical-name": "Taxoids"}, {"chemical-name": "Trastuzumab"}]}]}, "manufacturergroup": {"manufacturers": {"@type": "MNF", "manufacturer": "Hoffmann La Roche"}}}}, "item-info": {"copyright": {"$": "Copyright 2021 Elsevier B.V., All rights reserved.", "@type": "Elsevier"}, "external-source": "MEDLINE", "dbcollection": [{"$": "CABS"}, {"$": "EMBASE"}, {"$": "MEDL"}, {"$": "MOSYEA"}, {"$": "NURSNG"}, {"$": "REAXYSCAR"}, {"$": "SCOPUS"}, {"$": "Scopusbase"}], "history": {"date-created": {"@day": "12", "@timestamp": "BST 08:55:36", "@year": "2021", "@month": "01"}}, "itemidlist": {"itemid": [{"$": "613996934", "@idtype": "PUI"}, {"$": "2017010055", "@idtype": "CABS"}, {"$": "659899384", "@idtype": "CAR-ID"}, {"$": "20170023335", "@idtype": "EMBASE"}, {"$": "27918780", "@idtype": "MEDL"}, {"$": "2017003949", "@idtype": "MOSYEA"}, {"$": "2017011210", "@idtype": "NURSNG"}, {"$": "20170054390", "@idtype": "REAXYSCAR"}, {"$": "20173219389", "@idtype": "SCOPUS"}, {"$": "85008395149", "@idtype": "SCP"}, {"$": "85008395149", "@idtype": "SGR"}, {"$": "614376917", "@idtype": "PUIsecondary"}], "ce:doi": "10.1001/jama.2016.18305"}}, "tail": {"bibliography": {"@refcount": "25", "reference": [{"ref-fulltext": "Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin. 2006;56(4): 226-243.", "@id": "1", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "Targeted therapy of cancer: New prospects for antibodies and immunoconjugates"}, "refd-itemidlist": {"itemid": {"$": "33746836894", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "56", "@issue": "4"}, "pagerange": {"@first": "226", "@last": "243"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.M.", "@_fa": "true", "ce:surname": "Sharkey", "ce:indexed-name": "Sharkey R.M."}, {"@seq": "2", "ce:initials": "D.M.", "@_fa": "true", "ce:surname": "Goldenberg", "ce:indexed-name": "Goldenberg D.M."}]}, "ref-sourcetitle": "CA Cancer J Clin"}}, {"ref-fulltext": "Bellati F, Napoletano C, Gasparri ML, et al. Monoclonal antibodies in gynecological cancer: a critical point of view. Clin Dev Immunol. 2011;2011: 890758.", "@id": "2", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Monoclonal antibodies in gynecological cancer: A critical point of view"}, "refd-itemidlist": {"itemid": {"$": "84855593254", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "2011"}, "pagerange": {"@first": "890758"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Bellati", "ce:indexed-name": "Bellati F."}, {"@seq": "2", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Napoletano", "ce:indexed-name": "Napoletano C."}, {"@seq": "3", "ce:initials": "M.L.", "@_fa": "true", "ce:surname": "Gasparri", "ce:indexed-name": "Gasparri M.L."}], "et-al": null}, "ref-sourcetitle": "Clin Dev Immunol"}}, {"ref-fulltext": "Baer Ii WH, Maini A, Jacobs I. Barriers to the access and use of rituximab in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia: a physician survey. Pharmaceuticals (Basel). 2014;7(5):530-544.", "@id": "3", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Barriers to the access and use of rituximab in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia: A physician survey"}, "refd-itemidlist": {"itemid": {"$": "84900407291", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "7", "@issue": "5"}, "pagerange": {"@first": "530", "@last": "544"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "W.H.", "@_fa": "true", "ce:surname": "Baer Ii", "ce:indexed-name": "Baer Ii W.H."}, {"@seq": "2", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Maini", "ce:indexed-name": "Maini A."}, {"@seq": "3", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Jacobs", "ce:indexed-name": "Jacobs I."}]}, "ref-sourcetitle": "Pharmaceuticals (Basel)"}}, {"ref-fulltext": "Lammers P, Criscitiello C, Curigliano G, Jacobs I. Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: a physician survey in the United States and emerging markets. Pharmaceuticals (Basel). 2014;7 (9):943-953.", "@id": "4", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: A physician survey in the United States and emerging markets"}, "refd-itemidlist": {"itemid": {"$": "84928107043", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "7", "@issue": "9"}, "pagerange": {"@first": "943", "@last": "953"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Lammers", "ce:indexed-name": "Lammers P."}, {"@seq": "2", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Criscitiello", "ce:indexed-name": "Criscitiello C."}, {"@seq": "3", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Curigliano", "ce:indexed-name": "Curigliano G."}, {"@seq": "4", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Jacobs", "ce:indexed-name": "Jacobs I."}]}, "ref-sourcetitle": "Pharmaceuticals (Basel)"}}, {"ref-fulltext": "McCamish M,Woollett G.Worldwide experience with biosimilar development. MAbs. 2011;3(2): 209-217.", "@id": "5", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Worldwide experience with biosimilar development"}, "refd-itemidlist": {"itemid": {"$": "79952744875", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "3", "@issue": "2"}, "pagerange": {"@first": "209", "@last": "217"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "McCamish", "ce:indexed-name": "McCamish M."}, {"@seq": "2", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Woollett", "ce:indexed-name": "Woollett G."}]}, "ref-sourcetitle": "MAbs"}}, {"ref-fulltext": "Rugo HS, Linton KM, Cervi P, Rosenberg JA, Jacobs I. A clinician's guide to biosimilars in oncology. Cancer Treat Rev. 2016;46:73-79.", "@id": "6", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-title": {"ref-titletext": "A clinician's guide to biosimilars in oncology"}, "refd-itemidlist": {"itemid": {"$": "84966269149", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "46"}, "pagerange": {"@first": "73", "@last": "79"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "H.S.", "@_fa": "true", "ce:surname": "Rugo", "ce:indexed-name": "Rugo H.S."}, {"@seq": "2", "ce:initials": "K.M.", "@_fa": "true", "ce:surname": "Linton", "ce:indexed-name": "Linton K.M."}, {"@seq": "3", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Cervi", "ce:indexed-name": "Cervi P."}, {"@seq": "4", "ce:initials": "J.A.", "@_fa": "true", "ce:surname": "Rosenberg", "ce:indexed-name": "Rosenberg J.A."}, {"@seq": "5", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Jacobs", "ce:indexed-name": "Jacobs I."}]}, "ref-sourcetitle": "Cancer Treat Rev"}}, {"ref-fulltext": "Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32(33):3744-3752.", "@id": "7", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831"}, "refd-itemidlist": {"itemid": {"$": "84911908120", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "32", "@issue": "33"}, "pagerange": {"@first": "3744", "@last": "3752"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "E.A.", "@_fa": "true", "ce:surname": "Perez", "ce:indexed-name": "Perez E.A."}, {"@seq": "2", "ce:initials": "E.H.", "@_fa": "true", "ce:surname": "Romond", "ce:indexed-name": "Romond E.H."}, {"@seq": "3", "ce:initials": "V.J.", "@_fa": "true", "ce:surname": "Suman", "ce:indexed-name": "Suman V.J."}], "et-al": null}, "ref-sourcetitle": "J Clin Oncol"}}, {"ref-fulltext": "Piccart-GebhartMJ, Procter M, Leyland-Jones B, et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1659-1672.", "@id": "8", "ref-info": {"ref-publicationyear": {"@first": "2005"}, "ref-title": {"ref-titletext": "Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer"}, "refd-itemidlist": {"itemid": {"$": "26844503270", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "353", "@issue": "16"}, "pagerange": {"@first": "1659", "@last": "1672"}}, "ref-text": "Herceptin Adjuvant (HERA) Trial Study Team", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.J.", "@_fa": "true", "ce:surname": "Piccart-Gebhart", "ce:indexed-name": "Piccart-Gebhart M.J."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Procter", "ce:indexed-name": "Procter M."}, {"@seq": "3", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Leyland-Jones", "ce:indexed-name": "Leyland-Jones B."}], "et-al": null}, "ref-sourcetitle": "N Engl J Med"}}, {"ref-fulltext": "Slamon D, EiermannW, Robert N, et al; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-1283.", "@id": "9", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Adjuvant trastuzumab in HER2-positive breast cancer"}, "refd-itemidlist": {"itemid": {"$": "80053539103", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "365", "@issue": "14"}, "pagerange": {"@first": "1273", "@last": "1283"}}, "ref-text": "Breast Cancer International Research Group", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Slamon", "ce:indexed-name": "Slamon D."}, {"@seq": "2", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Eiermann", "ce:indexed-name": "Eiermann W."}, {"@seq": "3", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Robert", "ce:indexed-name": "Robert N."}], "et-al": null}, "ref-sourcetitle": "N Engl J Med"}}, {"ref-fulltext": "Bang YJ, Van Cutsem E, Feyereislova A, et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [published correction appears in Lancet. 2010;376(9749):1302]. Lancet. 2010;376(9742): 687-697.", "@id": "10", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial [published correction appears in Lancet. 2010;376(9749):1302]"}, "refd-itemidlist": {"itemid": {"$": "77956262693", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "376", "@issue": "9742"}, "pagerange": {"@first": "687", "@last": "697"}}, "ref-text": "ToGA Trial Investigators", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "Y.J.", "@_fa": "true", "ce:surname": "Bang", "ce:indexed-name": "Bang Y.J."}, {"@seq": "2", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Van Cutsem", "ce:indexed-name": "Van Cutsem E."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Feyereislova", "ce:indexed-name": "Feyereislova A."}], "et-al": null}, "ref-sourcetitle": "Lancet"}}, {"ref-fulltext": "Mylan Inc. Internal reports including results from Study MYL-Her-1001 and MYL-Her-1002. Presented at: Pharmacology 2015 Meeting of the British Pharmacological Society; December 15-17, 2015; London, England.", "@id": "11", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "refd-itemidlist": {"itemid": {"$": "85008355919", "@idtype": "SGR"}}, "ref-text": "Mylan Inc. Internal reports including results from Study MYL-Her-1001 and MYL-Her-1002, December 15-17, London, England", "ref-sourcetitle": "Pharmacology 2015 Meeting of the British Pharmacological Society"}}, {"ref-fulltext": "Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.", "@id": "12", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)"}, "refd-itemidlist": {"itemid": {"$": "57849117384", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "45", "@issue": "2"}, "pagerange": {"@first": "228", "@last": "247"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "E.A.", "@_fa": "true", "ce:surname": "Eisenhauer", "ce:indexed-name": "Eisenhauer E.A."}, {"@seq": "2", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Therasse", "ce:indexed-name": "Therasse P."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Bogaerts", "ce:indexed-name": "Bogaerts J."}], "et-al": null}, "ref-sourcetitle": "Eur J Cancer"}}, {"ref-fulltext": "Gasparini G, Gion M, Mariani L, et al. Randomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with HER-2 positive advanced breast cancer. Breast Cancer Res Treat. 2007;101(3):355-365.", "@id": "13", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Randomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with HER-2 positive advanced breast cancer"}, "refd-itemidlist": {"itemid": {"$": "33846477245", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "101", "@issue": "3"}, "pagerange": {"@first": "355", "@last": "365"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Gasparini", "ce:indexed-name": "Gasparini G."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Gion", "ce:indexed-name": "Gion M."}, {"@seq": "3", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Mariani", "ce:indexed-name": "Mariani L."}], "et-al": null}, "ref-sourcetitle": "Breast Cancer Res Treat"}}, {"ref-fulltext": "Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 formetastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11): 783-792.", "@id": "14", "ref-info": {"ref-publicationyear": {"@first": "2001"}, "ref-title": {"ref-titletext": "Use of chemotherapy plus a monoclonal antibody against HER2 formetastatic breast cancer that overexpresses HER2"}, "refd-itemidlist": {"itemid": {"$": "0035869407", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "344", "@issue": "11"}, "pagerange": {"@first": "783", "@last": "792"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.J.", "@_fa": "true", "ce:surname": "Slamon", "ce:indexed-name": "Slamon D.J."}, {"@seq": "2", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Leyland-Jones", "ce:indexed-name": "Leyland-Jones B."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Shak", "ce:indexed-name": "Shak S."}], "et-al": null}, "ref-sourcetitle": "N Engl J Med"}}, {"ref-fulltext": "Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positivemetastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol. 2005;23(19):4265-4274.", "@id": "15", "ref-info": {"ref-publicationyear": {"@first": "2005"}, "ref-title": {"ref-titletext": "Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positivemetastatic breast cancer administered as first-line treatment: The M77001 Study Group"}, "refd-itemidlist": {"itemid": {"$": "22344446208", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "23", "@issue": "19"}, "pagerange": {"@first": "4265", "@last": "4274"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Marty", "ce:indexed-name": "Marty M."}, {"@seq": "2", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Cognetti", "ce:indexed-name": "Cognetti F."}, {"@seq": "3", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Maraninchi", "ce:indexed-name": "Maraninchi D."}], "et-al": null}, "ref-sourcetitle": "J Clin Oncol"}}, {"ref-fulltext": "Baselga J, Cort\u00e9s J, Kim SB, et al; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel formetastatic breast cancer. N Engl J Med. 2012;366(2):109-119.", "@id": "16", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Pertuzumab plus trastuzumab plus docetaxel formetastatic breast cancer"}, "refd-itemidlist": {"itemid": {"$": "84862914692", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "366", "@issue": "2"}, "pagerange": {"@first": "109", "@last": "119"}}, "ref-text": "CLEOPATRA Study Group", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Baselga", "ce:indexed-name": "Baselga J."}, {"@seq": "2", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Cort\u00e9s", "ce:indexed-name": "Cortes J."}, {"@seq": "3", "ce:initials": "S.B.", "@_fa": "true", "ce:surname": "Kim", "ce:indexed-name": "Kim S.B."}], "et-al": null}, "ref-sourcetitle": "N Engl J Med"}}, {"ref-fulltext": "Singh SC, Bagnato KM. The economic implications of biosimilars. Am J Manag Care. 2015; 21(16)(suppl):s331-s340.", "@id": "17", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "The economic implications of biosimilars"}, "refd-itemidlist": {"itemid": {"$": "85012855515", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "21", "@issue": "16"}, "pagerange": {"@first": "s331", "@last": "s340"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.C.", "@_fa": "true", "ce:surname": "Singh", "ce:indexed-name": "Singh S.C."}, {"@seq": "2", "ce:initials": "K.M.", "@_fa": "true", "ce:surname": "Bagnato", "ce:indexed-name": "Bagnato K.M."}]}, "ref-sourcetitle": "Am J Manag Care"}}, {"ref-fulltext": "MulcahyMW, Predmore Z, Mattke S. The cost savings potential of biosimilar drugs in the United States. http://www.rand.org/pubs/perspectives/PE127.html. Published 2014. Accessed August 15, 2016.", "@id": "18", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-website": {"ce:e-address": {"$": "http://www.rand.org/pubs/perspectives/PE127.html", "@type": "email"}}, "refd-itemidlist": {"itemid": {"$": "84932169735", "@idtype": "SGR"}}, "ref-text": "Published, Accessed August 15, 2016", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.W.", "@_fa": "true", "ce:surname": "Mulcahy", "ce:indexed-name": "Mulcahy M.W."}, {"@seq": "2", "ce:initials": "Z.", "@_fa": "true", "ce:surname": "Predmore", "ce:indexed-name": "Predmore Z."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Mattke", "ce:indexed-name": "Mattke S."}]}, "ref-sourcetitle": "The Cost Savings Potential of Biosimilar Drugs in the United States"}}, {"ref-fulltext": "European Medicines Agency. Guideline on similar biological medicinal products. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/10/WC500176768.pdf. Published October 23, 2014. Accessed April 29, 2016.", "@id": "19", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-website": {"websitename": "European Medicines Agency", "ce:e-address": {"$": "http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/10/WC500176768.pdf", "@type": "email"}}, "refd-itemidlist": {"itemid": {"$": "85008355463", "@idtype": "SGR"}}, "ref-text": "Published October 23, 2014. Accessed April 29", "ref-sourcetitle": "Guideline on Similar Biological Medicinal Products"}}, {"ref-fulltext": "US Department of Health and Human Services; US Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291128.pdf. Published April 2015. Accessed April 29, 2016.", "@id": "20", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-website": {"ce:e-address": {"$": "http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291128.pdf", "@type": "email"}}, "refd-itemidlist": {"itemid": {"$": "84988676446", "@idtype": "SGR"}}, "ref-text": "US Department of Health and Human Services; US Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER), Published April 2015. Accessed April 29", "ref-sourcetitle": "Scientific Considerations in Demonstrating Biosimilarity to A Reference Product: Guidance for Industry"}}, {"ref-fulltext": "Expert Committee on Biological Standardization,World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). http://www.who.int/biologicals/areas/biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf. Published 2009. Accessed April 29, 2016.", "@id": "21", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-website": {"ce:e-address": {"$": "http://www.who.int/biologicals/areas/biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf", "@type": "email"}}, "refd-itemidlist": {"itemid": {"$": "84964601329", "@idtype": "SGR"}}, "ref-text": "Expert Committee on Biological Standardization, World Health Organization, Published 2009. Accessed April 29", "ref-sourcetitle": "Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs)"}}, {"ref-fulltext": "Gelmon KA, Boyle FM, Kaufman B, et al. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31. J Clin Oncol. 2015;33(14):1574-1583.", "@id": "22", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results of NCIC CTG MA.31"}, "refd-itemidlist": {"itemid": {"$": "84933564599", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "33", "@issue": "14"}, "pagerange": {"@first": "1574", "@last": "1583"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "K.A.", "@_fa": "true", "ce:surname": "Gelmon", "ce:indexed-name": "Gelmon K.A."}, {"@seq": "2", "ce:initials": "F.M.", "@_fa": "true", "ce:surname": "Boyle", "ce:indexed-name": "Boyle F.M."}, {"@seq": "3", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Kaufman", "ce:indexed-name": "Kaufman B."}], "et-al": null}, "ref-sourcetitle": "J Clin Oncol"}}, {"ref-fulltext": "Ellis PA, Barrios CH, EiermannW, et al. Phase III, randomized study of trastuzumab emtansine (T-DM1) \u00b1 pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: primary results from the MARIANNE study [abstract 507]. J Clin Oncol. 2015;33(suppl).", "@id": "23", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Phase III, randomized study of trastuzumab emtansine (T-DM1) \u00b1 pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study [abstract 507]"}, "refd-itemidlist": {"itemid": {"$": "84978968311", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "33"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.A.", "@_fa": "true", "ce:surname": "Ellis", "ce:indexed-name": "Ellis P.A."}, {"@seq": "2", "ce:initials": "C.H.", "@_fa": "true", "ce:surname": "Barrios", "ce:indexed-name": "Barrios C.H."}, {"@seq": "3", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Eiermann", "ce:indexed-name": "Eiermann W."}], "et-al": null}, "ref-sourcetitle": "J Clin Oncol"}}, {"ref-fulltext": "Ismael G, Hegg R, Muehlbauer S, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012;13(9):869-878.", "@id": "24", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): A phase 3, open-label, multicentre, randomised trial"}, "refd-itemidlist": {"itemid": {"$": "84865532999", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "13", "@issue": "9"}, "pagerange": {"@first": "869", "@last": "878"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Ismael", "ce:indexed-name": "Ismael G."}, {"@seq": "2", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Hegg", "ce:indexed-name": "Hegg R."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Muehlbauer", "ce:indexed-name": "Muehlbauer S."}], "et-al": null}, "ref-sourcetitle": "Lancet Oncol"}}, {"ref-fulltext": "Hegg R, Pienkowski T, Chen S, et al. Immunogenicity of trastuzumab intravenous and subcutaneous formulations in the phase III HannaH study. Presented at: ESMO Congress 2012 of the European Society for Medical Oncology; October 1, 2012; Vienna, Austria.", "@id": "25", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Immunogenicity of trastuzumab intravenous and subcutaneous formulations in the phase III HannaH study"}, "refd-itemidlist": {"itemid": {"$": "84921039035", "@idtype": "SGR"}}, "ref-text": "October 1, Vienna, Austria", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Hegg", "ce:indexed-name": "Hegg R."}, {"@seq": "2", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Pienkowski", "ce:indexed-name": "Pienkowski T."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Chen", "ce:indexed-name": "Chen S."}], "et-al": null}, "ref-sourcetitle": "ESMO Congress 2012 of the European Society for Medical Oncology"}}]}}}}, "affiliation": [{"affiliation-city": "Canonsburg", "@id": "60086729", "affilname": "Mylan Inc.", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60086729", "affiliation-country": "United States"}, {"affiliation-city": "Bangkok", "@id": "60199575", "affilname": "Siriraj Hospital", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575", "affiliation-country": "Thailand"}, {"affiliation-city": "Dnipro", "@id": "60070090", "affilname": "Dnipro State Medical University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60070090", "affiliation-country": "Ukraine"}, {"affiliation-city": "San Francisco", "@id": "60029881", "affilname": "UCSF Helen Diller Family Comprehensive Cancer Center", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60029881", "affiliation-country": "United States"}, {"affiliation-city": "Bangkok", "@id": "60028190", "affilname": "Chulalongkorn University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190", "affiliation-country": "Thailand"}, {"affiliation-city": "Freiburg im Breisgau", "@id": "60024805", "affilname": "Universit\u00e4tsklinikum Freiburg", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60024805", "affiliation-country": "Germany"}, {"affiliation-city": "Sumy", "@id": "60016511", "affilname": "Sumy State University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016511", "affiliation-country": "Ukraine"}, {"affiliation-city": "Baltimore", "@id": "60006183", "affilname": "Johns Hopkins Bloomberg School of Public Health", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006183", "affiliation-country": "United States"}, {"affiliation-city": "Manila", "@id": "127843511", "affilname": "Cardinal Santos Medical Center", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/127843511", "affiliation-country": "Philippines"}, {"affiliation-city": "Bengaluru", "@id": "121837736", "affilname": "Biocon Research Limited", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/121837736", "affiliation-country": "India"}, {"affiliation-city": "Tbilisi", "@id": "117925630", "affilname": "Golden Fleece 21 Century Health House Ltd", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/117925630", "affiliation-country": "Georgia"}, {"affiliation-city": "Vijayawada", "@id": "114003460", "affilname": "City Cancer Center", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/114003460", "affiliation-country": "India"}, {"affiliation-city": "Barcelona", "@id": "113802190", "affilname": "Quiron-Dexeus", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/113802190", "affiliation-country": "Spain"}, {"affiliation-city": "Nasik", "@id": "112923297", "affilname": "HCG Manavata Cancer Centre", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/112923297", "affiliation-country": "India"}, {"affiliation-city": "Kazan", "@id": "112755585", "affilname": "Regional Clinical Oncological Center", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/112755585", "affiliation-country": "Russian Federation"}, {"affiliation-city": "Taguig", "@id": "112662036", "affilname": "St. Luke's Medical Center Global City", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/112662036", "affiliation-country": "Philippines"}, {"affiliation-city": "Saint Petersburg (ex Leningrad)", "@id": "112632857", "affilname": "City Clinical Oncology Dispensary", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/112632857", "affiliation-country": "Russian Federation"}, {"affiliation-city": "Temuco", "@id": "110207140", "affilname": "Instituto Clinico Oncologico del Sur", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/110207140", "affiliation-country": "Chile"}, {"affiliation-city": "Tbilisi", "@id": "101407268", "affilname": "Institute of Clinical Oncology", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/101407268", "affiliation-country": "Georgia"}], "coredata": {"srctype": "j", "eid": "2-s2.0-85008395149", "dc:description": "IMPORTANCE Treatment with the anti-ERBB2 humanized monoclonal antibody trastuzumab and chemotherapy significantly improves outcome in patients with ERBB2 (HER2)-positive metastatic breast cancer; a clinically effective biosimilar may help increase access to this therapy. OBJECTIVE To compare the overall response rate and assess the safety of a proposed trastuzumab biosimilar plus a taxane or trastuzumab plus a taxane in patients without prior treatment for ERBB2-positivemetastatic breast cancer. DESIGN, SETTING, AND PARTICIPANTS Multicenter, double-blind, randomized, parallel-group, phase 3 equivalence study in patients with metastatic breast cancer. From December 2012 to August 2015, 500 patients were randomized 1:1 to receive a proposed biosimilar or trastuzumab plus a taxane. Chemotherapy was administered for at least 24 weeks followed by antibody alone until unacceptable toxic effects or disease progression occurred. INTERVENTIONS Proposed biosimilar (n = 230) or trastuzumab (n = 228) with a taxane. MAIN OUTCOMES AND MEASURES The primary outcomewasweek 24 overall response rate (ORR) defined as complete or partial response. Equivalence boundaries were 0.81 to 1.24 with a 90% CI for ORR ratio (proposed biosimilar/trastuzumab) and -15%to 15%with a 95% CI for ORR difference. Secondary outcome measures included time to tumor progression, progression-free and overall survival at week 48, and adverse events. RESULTS Among500women randomized, the intention-to-treat population included 458 women (mean [SD] age, 53.6 [11.11] years) and the safety population included 493women. TheORRwas 69.6%(95%CI, 63.62%-75.51%) for the proposed biosimilar vs 64.0%(95%CI, 57.81%-70.26%) for trastuzumab. TheORRratio (1.09;90%CI,0.974-1.211) andORRdifference (5.53; 95%CI, -3.08 to 14.04)were within the equivalence boundaries.Atweek 48, therewas no statistically significant difference with the proposed biosimilar vs trastuzumab for time to tumor progression (41.3%vs 43.0%; -1.7%; 95%CI, -11.1%to 6.9%), progression-free survival (44.3% vs 44.7%; -0.4%; 95%CI, -9.4%to 8.7%), or overall survival (89.1%vs 85.1%; 4.0%; 95%CI, -2.1%to 10.3%). In the proposed biosimilar and trastuzumab groups, 239 (98.6%) and 233 (94.7%) had at least 1 adverse event, the mostcommonincluding neutropenia (57.5%vs 53.3%), peripheral neuropathy (23.1%vs 24.8%), and diarrhea (20.6%vs 20.7%). CONCLUSIONS AND RELEVANCE Amongwomen with ERBB2-positivemetastatic breast cancer receiving taxanes, the use of a proposed trastuzumab biosimilar compared with trastuzumab resulted in an equivalent overall response rate at 24 weeks. Further study is needed to assess safety and long-term clinical outcome.", "pubmed-id": "27918780", "prism:coverDate": "2017-01-03", "prism:aggregationType": "Journal", "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85008395149", "dc:creator": {"author": [{"ce:given-name": "Hope S.", "preferred-name": {"ce:given-name": "Hope S.", "ce:initials": "H.S.", "ce:surname": "Rugo", "ce:indexed-name": "Rugo H.S."}, "@seq": "1", "ce:initials": "H.S.", "@_fa": "true", "affiliation": {"@id": "60029881", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60029881"}, "ce:degrees": "MD", "ce:surname": "Rugo", "@auid": "57200920500", "author-url": "https://api.elsevier.com/content/author/author_id/57200920500", "ce:indexed-name": "Rugo H.S."}]}, "link": [{"@_fa": "true", "@rel": "self", "@href": "https://api.elsevier.com/content/abstract/scopus_id/85008395149"}, {"@_fa": "true", "@rel": "scopus", "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85008395149&origin=inward"}, {"@_fa": "true", "@rel": "scopus-citedby", "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85008395149&origin=inward"}], "source-id": "85291", "citedby-count": "120", "prism:volume": "317", "subtype": "ar", "dc:title": "Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: A randomized clinical trial", "openaccess": "1", "prism:issn": "15383598 00987484", "prism:issueIdentifier": "1", "subtypeDescription": "Article", "prism:publicationName": "JAMA - Journal of the American Medical Association", "prism:pageRange": "37-47", "prism:endingPage": "47", "openaccessFlag": "true", "prism:doi": "10.1001/jama.2016.18305", "prism:startingPage": "37", "dc:identifier": "SCOPUS_ID:85008395149", "dc:publisher": "American Medical Association"}, "idxterms": {"mainterm": [{"$": "Adult", "@weight": "b", "@candidate": "n"}, {"$": "Aged", "@weight": "b", "@candidate": "n"}, {"$": "Aged, 80 and over", "@weight": "b", "@candidate": "n"}, {"$": "Antineoplastic Agents", "@weight": "b", "@candidate": "n"}, {"$": "Antineoplastic Agents, Phytogenic", "@weight": "b", "@candidate": "n"}, {"$": "Antineoplastic Combined Chemotherapy Protocols", "@weight": "b", "@candidate": "n"}, {"$": "Biosimilar Pharmaceuticals", "@weight": "b", "@candidate": "n"}, {"$": "Breast Neoplasms", "@weight": "b", "@candidate": "n"}, {"$": "Disease Progression", "@weight": "b", "@candidate": "n"}, {"$": "Double-Blind Method", "@weight": "b", "@candidate": "n"}, {"$": "Female", "@weight": "b", "@candidate": "n"}, {"$": "Humans", "@weight": "b", "@candidate": "n"}, {"$": "Intention to Treat Analysis", "@weight": "b", "@candidate": "n"}, {"$": "Middle Aged", "@weight": "b", "@candidate": "n"}, {"$": "Paclitaxel", "@weight": "b", "@candidate": "n"}, {"$": "Receptor, ErbB-2", "@weight": "a", "@candidate": "n"}, {"$": "Remission Induction", "@weight": "b", "@candidate": "n"}, {"$": "Survival Analysis", "@weight": "b", "@candidate": "n"}, {"$": "Taxoids", "@weight": "b", "@candidate": "n"}, {"$": "Therapeutic Equipoise", "@weight": "b", "@candidate": "n"}, {"$": "Time Factors", "@weight": "b", "@candidate": "n"}, {"$": "Trastuzumab", "@weight": "b", "@candidate": "n"}]}, "language": {"@xml:lang": "eng"}, "authkeywords": null, "subject-areas": {"subject-area": [{"@_fa": "true", "$": "Medicine (all)", "@code": "2700", "@abbrev": "MEDI"}]}, "authors": {"author": [{"ce:given-name": "Hope S.", "preferred-name": {"ce:given-name": "Hope S.", "ce:initials": "H.S.", "ce:surname": "Rugo", "ce:indexed-name": "Rugo H.S."}, "@seq": "1", "ce:initials": "H.S.", "@_fa": "true", "affiliation": {"@id": "60029881", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60029881"}, "ce:degrees": "MD", "ce:surname": "Rugo", "@auid": "57200920500", "author-url": "https://api.elsevier.com/content/author/author_id/57200920500", "ce:indexed-name": "Rugo H.S."}, {"ce:given-name": "Abhijit", "preferred-name": {"ce:given-name": "Abhijit", "ce:initials": "A.", "ce:surname": "Barve", "ce:indexed-name": "Barve A."}, "@seq": "2", "ce:initials": "A.", "@_fa": "true", "affiliation": [{"@id": "121837736", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/121837736"}, {"@id": "60086729", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60086729"}], "ce:degrees": "MD, PhD, MBA", "ce:surname": "Barve", "@auid": "56670991200", "author-url": "https://api.elsevier.com/content/author/author_id/56670991200", "ce:indexed-name": "Barve A."}, {"ce:given-name": "Cornelius F.", "preferred-name": {"ce:given-name": "Cornelius F.", "ce:initials": "C.F.", "ce:surname": "Waller", "ce:indexed-name": "Waller C.F."}, "@seq": "3", "ce:initials": "C.F.", "@_fa": "true", "affiliation": {"@id": "60024805", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60024805"}, "ce:degrees": "MD", "ce:surname": "Waller", "@auid": "7006001726", "author-url": "https://api.elsevier.com/content/author/author_id/7006001726", "ce:indexed-name": "Waller C.F."}, {"ce:given-name": "Miguel", "preferred-name": {"ce:given-name": "Miguel", "ce:initials": "M.", "ce:surname": "Hernandez-Bronchud", "ce:indexed-name": "Hernandez-Bronchud M."}, "@seq": "4", "ce:initials": "M.", "@_fa": "true", "affiliation": {"@id": "113802190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/113802190"}, "ce:degrees": "MD, PhD", "ce:surname": "Hernandez-Bronchud", "@auid": "6602840533", "author-url": "https://api.elsevier.com/content/author/author_id/6602840533", "ce:indexed-name": "Hernandez-Bronchud M."}, {"ce:given-name": "Jay", "preferred-name": {"ce:given-name": "Jay", "ce:initials": "J.", "ce:surname": "Herson", "ce:indexed-name": "Herson J."}, "@seq": "5", "ce:initials": "J.", "@_fa": "true", "affiliation": {"@id": "60006183", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006183"}, "ce:degrees": "PhD", "ce:surname": "Herson", "@auid": "7004312660", "author-url": "https://api.elsevier.com/content/author/author_id/7004312660", "ce:indexed-name": "Herson J."}, {"ce:given-name": "Jinyu", "preferred-name": {"ce:given-name": "Jinyu", "ce:initials": "J.", "ce:surname": "Yuan", "ce:indexed-name": "Yuan J."}, "@seq": "6", "ce:initials": "J.", "@_fa": "true", "affiliation": {"@id": "60086729", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60086729"}, "ce:degrees": "PhD", "ce:surname": "Yuan", "@auid": "57192835540", "author-url": "https://api.elsevier.com/content/author/author_id/57192835540", "ce:indexed-name": "Yuan J."}, {"ce:given-name": "Rajiv", "preferred-name": {"ce:given-name": "Rajiv", "ce:initials": "R.", "ce:surname": "Sharma", "ce:indexed-name": "Sharma R."}, "@seq": "7", "ce:initials": "R.", "@_fa": "true", "affiliation": {"@id": "60086729", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60086729"}, "ce:degrees": "MBBS, MS", "ce:surname": "Sharma", "@auid": "57192835055", "author-url": "https://api.elsevier.com/content/author/author_id/57192835055", "ce:indexed-name": "Sharma R."}, {"ce:given-name": "Mark", "preferred-name": {"ce:given-name": "Mark", "ce:initials": "M.", "ce:surname": "Baczkowski", "ce:indexed-name": "Baczkowski M."}, "@seq": "8", "ce:initials": "M.", "@_fa": "true", "affiliation": {"@id": "60086729", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60086729"}, "ce:degrees": "MS, RPh", "ce:surname": "Baczkowski", "@auid": "57192833633", "author-url": "https://api.elsevier.com/content/author/author_id/57192833633", "ce:indexed-name": "Baczkowski M."}, {"ce:given-name": "Mudgal", "preferred-name": {"ce:given-name": "Mudgal", "ce:initials": "M.", "ce:surname": "Kothekar", "ce:indexed-name": "Kothekar M."}, "@seq": "9", "ce:initials": "M.", "@_fa": "true", "affiliation": {"@id": "121837736", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/121837736"}, "ce:degrees": "MD", "ce:surname": "Kothekar", "@auid": "57192835755", "author-url": "https://api.elsevier.com/content/author/author_id/57192835755", "ce:indexed-name": "Kothekar M."}, {"ce:given-name": "Subramanian", "preferred-name": {"ce:given-name": "Subramanian", "ce:initials": "S.", "ce:surname": "Loganathan", "ce:indexed-name": "Loganathan S."}, "@seq": "10", "ce:initials": "S.", "@_fa": "true", "affiliation": {"@id": "121837736", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/121837736"}, "ce:degrees": "MD", "ce:surname": "Loganathan", "@auid": "57218253315", "author-url": "https://api.elsevier.com/content/author/author_id/57218253315", "ce:indexed-name": "Loganathan S."}, {"ce:given-name": "Alexey", "preferred-name": {"ce:given-name": "Alexey", "ce:initials": "A.", "ce:surname": "Manikhas", "ce:indexed-name": "Manikhas A."}, "@seq": "11", "ce:initials": "A.", "@_fa": "true", "affiliation": {"@id": "112632857", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/112632857"}, "ce:degrees": "MD", "ce:surname": "Manikhas", "@auid": "6507130338", "author-url": "https://api.elsevier.com/content/author/author_id/6507130338", "ce:indexed-name": "Manikhas A."}, {"ce:given-name": "Igor", "preferred-name": {"ce:given-name": "Igor", "ce:initials": "I.", "ce:surname": "Bondarenko", "ce:indexed-name": "Bondarenko I."}, "@seq": "12", "ce:initials": "I.", "@_fa": "true", "affiliation": {"@id": "60070090", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60070090"}, "ce:degrees": "MD", "ce:surname": "Bondarenko", "@auid": "24729417400", "author-url": "https://api.elsevier.com/content/author/author_id/24729417400", "ce:indexed-name": "Bondarenko I."}, {"ce:given-name": "Guzel", "preferred-name": {"ce:given-name": "Guzel", "ce:initials": "G.", "ce:surname": "Mukhametshina", "ce:indexed-name": "Mukhametshina G."}, "@seq": "13", "ce:initials": "G.", "@_fa": "true", "affiliation": {"@id": "112755585", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/112755585"}, "ce:degrees": "MD", "ce:surname": "Mukhametshina", "@auid": "57215937870", "author-url": "https://api.elsevier.com/content/author/author_id/57215937870", "ce:indexed-name": "Mukhametshina G."}, {"ce:given-name": "Gia", "preferred-name": {"ce:given-name": "Gia", "ce:initials": "G.", "ce:surname": "Nemsadze", "ce:indexed-name": "Nemsadze G."}, "@seq": "14", "ce:initials": "G.", "@_fa": "true", "affiliation": {"@id": "101407268", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/101407268"}, "ce:degrees": "MD, PhD", "ce:surname": "Nemsadze", "@auid": "57188567636", "author-url": "https://api.elsevier.com/content/author/author_id/57188567636", "ce:indexed-name": "Nemsadze G."}, {"ce:given-name": "Joseph D.", "preferred-name": {"ce:given-name": "Joseph D.", "ce:initials": "J.D.", "ce:surname": "Parra", "ce:indexed-name": "Parra J.D."}, "@seq": "15", "ce:initials": "J.D.", "@_fa": "true", "affiliation": {"@id": "112662036", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/112662036"}, "ce:degrees": "MD", "ce:surname": "Parra", "@auid": "57192829649", "author-url": "https://api.elsevier.com/content/author/author_id/57192829649", "ce:indexed-name": "Parra J.D."}, {"ce:given-name": "Maria Luisa T.", "preferred-name": {"ce:given-name": "Maria Luisa T.", "ce:initials": "M.L.T.", "ce:surname": "Abesamis-Tiambeng", "ce:indexed-name": "Abesamis-Tiambeng M.L.T."}, "@seq": "16", "ce:initials": "M.L.T.", "@_fa": "true", "affiliation": {"@id": "127843511", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/127843511"}, "ce:degrees": "MD", "ce:surname": "Abesamis-Tiambeng", "@auid": "57192835193", "author-url": "https://api.elsevier.com/content/author/author_id/57192835193", "ce:indexed-name": "Abesamis-Tiambeng M.L.T."}, {"ce:given-name": "Kakhaber", "preferred-name": {"ce:given-name": "Kakhaber", "ce:initials": "K.", "ce:surname": "Baramidze", "ce:indexed-name": "Baramidze K."}, "@seq": "17", "ce:initials": "K.", "@_fa": "true", "affiliation": {"@id": "117925630", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/117925630"}, "ce:degrees": "MD, PhD", "ce:surname": "Baramidze", "@auid": "57192832810", "author-url": "https://api.elsevier.com/content/author/author_id/57192832810", "ce:indexed-name": "Baramidze K."}, {"ce:given-name": "Charuwan", "preferred-name": {"ce:given-name": "Charuwan", "ce:initials": "C.", "ce:surname": "Akewanlop", "ce:indexed-name": "Akewanlop C."}, "@seq": "18", "ce:initials": "C.", "@_fa": "true", "affiliation": {"@id": "60199575", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575"}, "ce:degrees": "MD", "ce:surname": "Akewanlop", "@auid": "6507727204", "author-url": "https://api.elsevier.com/content/author/author_id/6507727204", "ce:indexed-name": "Akewanlop C."}, {"ce:given-name": "Ihor", "preferred-name": {"ce:given-name": "Ihor", "ce:initials": "I.", "ce:surname": "Vynnychenko", "ce:indexed-name": "Vynnychenko I."}, "@seq": "19", "ce:initials": "I.", "@_fa": "true", "affiliation": {"@id": "60016511", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016511"}, "ce:degrees": "MD", "ce:surname": "Vynnychenko", "@auid": "24781268000", "author-url": "https://api.elsevier.com/content/author/author_id/24781268000", "ce:indexed-name": "Vynnychenko I."}, {"ce:given-name": "Virote", "preferred-name": {"ce:given-name": "Virote", "ce:initials": "V.", "ce:surname": "Sriuranpong", "ce:indexed-name": "Sriuranpong V."}, "@seq": "20", "ce:initials": "V.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:degrees": "MD", "ce:surname": "Sriuranpong", "@auid": "6603599644", "author-url": "https://api.elsevier.com/content/author/author_id/6603599644", "ce:indexed-name": "Sriuranpong V."}, {"ce:given-name": "Gopichand", "preferred-name": {"ce:given-name": "Gopichand", "ce:initials": "G.", "ce:surname": "Mamillapalli", "ce:indexed-name": "Mamillapalli G."}, "@seq": "21", "ce:initials": "G.", "@_fa": "true", "affiliation": {"@id": "114003460", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/114003460"}, "ce:degrees": "MS, MCh", "ce:surname": "Mamillapalli", "@auid": "57192832827", "author-url": "https://api.elsevier.com/content/author/author_id/57192832827", "ce:indexed-name": "Mamillapalli G."}, {"ce:given-name": "Sirshendu", "preferred-name": {"ce:given-name": "Sirshendu", "ce:initials": "S.", "ce:surname": "Ray", "ce:indexed-name": "Ray S."}, "@seq": "22", "ce:initials": "S.", "@_fa": "true", "affiliation": {"@id": "112923297", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/112923297"}, "ce:degrees": "MS", "ce:surname": "Ray", "@auid": "57214048627", "author-url": "https://api.elsevier.com/content/author/author_id/57214048627", "ce:indexed-name": "Ray S."}, {"ce:given-name": "Eduardo P.", "preferred-name": {"ce:given-name": "Eduardo P.", "ce:initials": "E.P.", "ce:surname": "Yanez Ruiz", "ce:indexed-name": "Yanez Ruiz E.P."}, "@seq": "23", "ce:initials": "E.P.", "@_fa": "true", "affiliation": {"@id": "110207140", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/110207140"}, "ce:degrees": "MD", "ce:surname": "Yanez Ruiz", "@auid": "57192839215", "author-url": "https://api.elsevier.com/content/author/author_id/57192839215", "ce:indexed-name": "Yanez Ruiz E.P."}, {"ce:given-name": "Eduardo", "preferred-name": {"ce:given-name": "Eduardo", "ce:initials": "E.", "ce:surname": "Pennella", "ce:indexed-name": "Pennella E."}, "@seq": "24", "ce:initials": "E.", "@_fa": "true", "affiliation": {"@id": "60086729", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60086729"}, "ce:degrees": "MD, MBA", "ce:surname": "Pennella", "@auid": "57217897584", "author-url": "https://api.elsevier.com/content/author/author_id/57217897584", "ce:indexed-name": "Pennella E."}]}}}